Hidoc Dr | Medical Learning App for Doctors

Today's Updates

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Published Date: 12 Feb 2026

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Published Date: 12 Feb 2026

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

Published Date: 12 Feb 2026

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Published Date: 12 Feb 2026

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD Daniel M. Siegel, MD

Published Date: 12 Feb 2026

Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

7 Pulmonology Headlines You Missed in January 2026

Published Date: 12 Feb 2026

7 Pulmonology Headlines You Missed in January 2026

Knowledge Hub

Oncology

Giant Sebaceous Cyst of the Scalp Mimicking a Soft Tissue Tumor: A Case Study

A rare giant sebaceous cyst of the scalp presenting as a soft tissue tumor case study.

Oncology

Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides

Precision cancer care using theranostics and radioligand therapy enhances targeted treatment and patient outcomes.

Oncology

Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization

Explore strategies for optimizing oncology trials, enhancing recruitment, decentralization, diversity, and patient-centered care.

Oncology

Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies

Enhance cancer care with multidisciplinary strategies, supportive therapies, and patient-centered interventions for better outcomes.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD Daniel M. Siegel, MD

7 Pulmonology Headlines You Missed in January 2026

Knowledge Hub

Giant Sebaceous Cyst of the Scalp Mimicking a Soft Tissue Tumor: A Case Study

Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides

Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization

Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies

The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies

Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond

Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

American College of Physicians Policy Paper Recommends Retiring 'Provider' Term for Physicians Isabella Ciccone, MPH

CD-38 Monoclonal Antibody Daratumumab Shows Promise as Treatment for NMOSD in Phase 3 DAWN Study Marco Meglio

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD Daniel M. Siegel, MD

7 Pulmonology Headlines You Missed in January 2026

Knowledge Hub

Giant Sebaceous Cyst of the Scalp Mimicking a Soft Tissue Tumor: A Case Study

Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides

Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization

Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies

The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies

Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond

Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views